Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 9/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.51 |
| ▸ | HPGDS | O60760 | 3/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27723676 | 0.85 | SCN2A (0.53) | SCN2ANPY5RHPGDSSCN9A | |
| SCHEMBL27703255 | 0.83 | SCN2A (0.54) | SCN2ANPY5RHPGDSSCN9ATRPV1 | |
| SCHEMBL27723683 | 0.78 | TNKS (0.49) | SCN2ASCN9AS1PR1 | |
| SCHEMBL28773007 | 0.77 | TNKS (0.51) | SCN2ASCN9AS1PR1S1PR3 | |
| SCHEMBL6027461 | 0.77 | SCN2A (0.56) | SCN2ANPY5RHPGDS | |
| SCHEMBL1926441 | 0.74 | TSHR (0.70) | S1PR1S1PR3PDE3BPDE3A | |
| SCHEMBL28540057 | 0.74 | SCN2A (1.00) | SCN2ANPY5RHPGDSTRPV1 | |
| SCHEMBL6026939 | 0.74 | NPY5R (0.64) | SCN2ANPY5RHPGDSTRPV1 | |
| SCHEMBL4617647 | 0.73 | NPC1 (0.62) | S1PR1S1PR3PDE3BPDE3A | |
| SCHEMBL17283469 | 0.72 | SCN2A (0.96) | SCN2ANPY5RHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101184739-A | Polycyclic * diazoles and iso- * azoles and their use as ligands for the S1P receptor | NOVARTIS AG (CH) | 2008-05-21 | — | — | CN | disclosed |